Ouch, Canada! Prexige Withdrawn From Yet Another Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.